

# NHS Kernow - Disclosure Log Freedom of Information Requests August 2019

# Contents

Continuing healthcare	3
FOI 76390 Continuing healthcare applications	3
FOI 76190 Continuing healthcare information	4
FOI 76180 Continuing healthcare applications	5
Contracts	6
FOI 76250 Termination of services	6
FOI 76140 Number of tests	7
GP Spend	8
FOI 75980 Community health services	8
Individual funding requests	9
FOI 76320 Limited clinical effectiveness	9
FOI 76230 Exceptional cases	11
Long term conditions	12
FOI 76210 Blood glucose formulary	12
FOI 75990 Blood glucose formulary	12
Mental health and learning disabilities	13
FOI 76600 Bariatric services	13
Miscellaneous	14
FOI 76310 Services no longer funded	14
FOI 76080 Palliative care	14
Organisation	15
FOI 76530 Organisation structure	15
FOI 76470 Transformation	16
FOI 76440 Primary care networks	18
FOI 76430 Primary care networks	19
FOI 76300 Primary care networks	19
FOI 76170 Primary care networks	20
Patient safety and experience	21
FOI 76350 Deep vein thrombosis (DVT)	21
FOI 76240 Prescribing recommendations	27
Prescribing and pharmacies	28
FOI 76550 Enhanced service contracts	28
Referral management	29
FOI 76460 Procedures of limited clinical effectiveness	29
FOI 76410 Glaucoma	30
FOI 76290 Referral triage service	31

Vomen's health	32
FOI 76590 IVF treatment	32

Information provided under the Freedom of Information Act may be reused in accordance with the Open Government License (OGL). Full details of which can be found on line <u>http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/</u>.

You may: copy, publish, distribute and transmit the Information; adapt the Information; exploit the Information commercially and non-commercially for example, by combining it with other Information, or by including it in your own product or application. However NHS Kernow must be acknowledged as the source of the information and provide a link to the OGL.

This licence does not grant you any right to use the Information in a way that suggests any official status or that the Information Provider and/or Licensor endorse you or your use of the Information.

All appendices for this disclosure log are available upon request by emailing KCCG.FOI@nhs.net with the appropriate FOI reference below.

# **Continuing healthcare**

## FOI 76390 Continuing healthcare applications

Date i receiv	equest ved:	20/08/2019- clarification received 30/08/2019	FOI ref:	76390
Requ	ested information	tion:		
Please could you provide me with the following information regarding NHS continuing health care (CHC) payments in the five years up to the end of the 2018-2019 financial year:				
	<ol> <li>The amount of funding the CCG has paid out as a result of retrospective CHC claims, broken down by year</li> </ol>			
<ol> <li>The number of people who have had their CHC funding withdrawn, broken down by year – clarification provided - A reassessment after a change in need was identified during review</li> </ol>				
<u> </u>	<b>T</b> he manual and a	<b>f</b>		

3. The number of people who have undergone reassessments for their CHC funding, broken down by year

#### Response:

Information is provided for each financial year ended 31 March.

1.	2014/2015	£139,605.99
	2015/2016	£218,947.67
	2016/2017	£28,283.87
	2017/2018	£19,323.13
	2018/2019	£35,229.46
2.	2014/2015	9
	2015/2016	38
	2016/2017	25
	2017/2018	34
	2018/2019	20
3.	2014/2015	262
	2015/2016	328
	2016/2017	331
	2017/2018	364
	2018/2019	279
A 44 a - 1	h m a m t ( a ) :	
	hment(s):	
none		
	response se	nt:
24/00	10010	

24/09/2019

# FOI 76190 Continuing healthcare information

Date request received:	09/08/2019	FOI ref:	76190	
<b>Requested informa</b>	tion:			
Our request relates to claims pursued for NHS funded continuing healthcare under the scheme announced by the Department of Health in 2012. Therefore, registered with the Clinical Commissioning Groups (CCGs) before September 2012 (for claims involving periods of care from 1 April 2004 to 31 March 2011) and 31 March 2013 (for claims involving periods of care from 1 April 2011 to 31 March 2012).				
Our request therefore relates to claims involving previously un-assessed periods of care ("PUPoC") and claims were any assessments completed at the time were deemed flawed under the October 2012 guidance, NHS Continuing Healthcare: Dealing with requests for assessments for un-assessed periods of care.				
In respect of the claims, please provide us with the following information:				
1. How many P	UPoC cases have bee	en completed by or on	behalf of the CCG	

- 2. How many PUPoC cases are still open.
- 3. How many of the cases referred to in 1 above have been successful, (i.e.

redress paid)

- 4. How many PUPoC cases are waiting for redress (eligibility awarded and redress to be made)
- 5. Please provide the total amount paid in redress to claimants. Please provide this amount annually.
- 6. In relation to 4 above, please provide the total amount paid in interest to claimants. Please provide this information annually.
- If applicable, please confirm the total amount paid by the CCG to commission third parties (CSU and/or private companies) to undertake retrospective PUPoC claims.

#### **Response:**

- 1. 574
- 2. None
- 3. 101
- 4. 2
- 5. See attached spreadsheet
- 6. See attached spreadsheet
- 7. None, process completed in house

#### Attachment(s):

Yes - NHS Kernow FOI 76190 - PUPC Redress Figures

Date response sent:

04/09/2019

## FOI 76180 Continuing healthcare applications

Date requ received:	est (	8/08/2019	FOI ref:	76180	
Requeste	d informatio	on:			
Request for information under the Freedom of Information Act and in relation to assessments undertaken for NHS Continuing Healthcare.					
<ol> <li>Between 1 January 2017 to 31 July 2019:         <ul> <li>a) How many NHS continuing healthcare assessments (Decision Support Tools or fast track assessments) were undertaken;</li> <li>b) How many of the above assessments recommended eligibility for NHS continuing healthcare; and</li> <li>c) How many of the above eligible recommendations were overturned or granted by the CCG.</li> </ul> </li> </ol>					
Please provide this data in annual figures or quarters.					
Response	):				
Year to 31	a. Fasttrack Referrals	b. Fasttrac	ks a. DST Assessm	b. DST Eligible nents decision	

March					
2017	1551	1542	562	152	
2018	1522	1513	691	169	
2019	942	942	412	78	
c. None	c. None Attachment(s):				
none					
Date response sent:					
04/09/2019					

# Contracts

# FOI 76250 Termination of services

Date receive		13/08/2019	FOI ref:	76250	
Reque	sted information	tion:			
	<ol> <li>Over the past three financial years (2016/17 to 2018/19 inclusive), in instances where your CCG has awarded contracts to private providers (i.e. non-NHS, independent sector providers, excluding charities and social enterprise) to provide NHS services, how many have been ended by the private providers before the end of the contracted period? Please provide the following details where possible:         <ul> <li>a. The name of the provider</li> <li>b. The length and value of the contract, and the nature of the service being provided</li> <li>c. The reason for the premature termination</li> <li>d. The amount of time left to run on the contract at the point at which it was terminated</li> <li>e. How continuity of service was guaranteed following the termination</li> <li>f. If any termination payment was paid, and how much that payment was (i.e. was any money paid to compensate for the premature cancellation of the contract)</li> </ul> </li> </ol>				
3.	with private pr	e period, has the CCG oviders to provide NH riod? As before, pleas ntracts in total has the od?	S services before the e provide details when	end of the e possible.	
Respo	nse:				
-					
1.	one				

Version 1

<ul> <li>a. Regional Hearing Specialists Limited</li> <li>b. This contract was awarded as an "Any Willing Provider" service for audiology (Hearing Aid assessment, supply and fitting for over 55 years of age) Commenced 1 April 2013 to 31 March 2016 with an option to extend until 31 March 2017 Annual spend variable but circa £85k per annum end March 2016.</li> <li>c. The Provider went out of business.</li> <li>d. 11 months of the extended period.</li> <li>e. New patients were sign posted to other Providers of this service, commissioned by the CCG, via their GPs. Existing patients were advised by the outgoing Provider to go back to their GP for a new referral. Hearing test prescription data, performed by Regional Hearing Specialists Limited, was made available from their Parent Company.</li> <li>f. None</li> <li>2. None</li> <li>3. 2016/2017 inclusive 2016/2017 – 133 (not including NHS or Third sector) 2017/2018 – 270 (not including NHS or Third sector) 2018/2019 – No longer recorded in this way</li> </ul>		a Decisional Liberting Creativitate Limited
<ul> <li>audiology (Hearing Aid assessment, supply and fitting for over 55 years of age) Commenced 1 April 2013 to 31 March 2016 with an option to extend until 31 March 2017 Annual spend variable but circa £85k per annum end March 2016.</li> <li>c. The Provider went out of business.</li> <li>d. 11 months of the extended period.</li> <li>e. New patients were sign posted to other Providers of this service, commissioned by the CCG, via their GPs. Existing patients were advised by the outgoing Provider to go back to their GP for a new referral. Hearing test prescription data, performed by Regional Hearing Specialists Limited, was made available from their Parent Company.</li> <li>f. None</li> <li>2. None</li> <li>3. 2016/2017 inclusive 2016/2017 – 133 (not including NHS or Third sector) 2017/2018 – 270 (not including NHS or Third sector) 2018/2019 – No longer recorded in this way</li> </ul>		
<ul> <li>of age) Commenced 1 April 2013 to 31 March 2016 with an option to extend until 31 March 2017 Annual spend variable but circa £85k per annum end March 2016.</li> <li>c. The Provider went out of business.</li> <li>d. 11 months of the extended period.</li> <li>e. New patients were sign posted to other Providers of this service, commissioned by the CCG, via their GPs. Existing patients were advised by the outgoing Provider to go back to their GP for a new referral. Hearing test prescription data, performed by Regional Hearing Specialists Limited, was made available from their Parent Company.</li> <li>f. None</li> <li>2. None</li> <li>3. 2016/2017 inclusive 2016/2017 - 133 (not including NHS or Third sector) 2017/2018 - 270 (not including NHS or Third sector) 2018/2019 - No longer recorded in this way</li> </ul>		
<ul> <li>extend until 31 March 2017 Annual spend variable but circa £85k per annum end March 2016.</li> <li>c. The Provider went out of business.</li> <li>d. 11 months of the extended period.</li> <li>e. New patients were sign posted to other Providers of this service, commissioned by the CCG, via their GPs. Existing patients were advised by the outgoing Provider to go back to their GP for a new referral. Hearing test prescription data, performed by Regional Hearing Specialists Limited, was made available from their Parent Company.</li> <li>f. None</li> <li>2. None</li> <li>3. 2016/2017 inclusive 2016/2017 – 133 (not including NHS or Third sector) 2017/2018 – 270 (not including NHS or Third sector) 2018/2019 – No longer recorded in this way</li> </ul>		
<ul> <li>annum end March 2016.</li> <li>c. The Provider went out of business.</li> <li>d. 11 months of the extended period.</li> <li>e. New patients were sign posted to other Providers of this service, commissioned by the CCG, via their GPs. Existing patients were advised by the outgoing Provider to go back to their GP for a new referral. Hearing test prescription data, performed by Regional Hearing Specialists Limited, was made available from their Parent Company.</li> <li>f. None</li> <li>2. None</li> <li>3. 2016/2017 inclusive 2016/2017 – 133 (not including NHS or Third sector) 2017/2018 – 270 (not including NHS or Third sector) 2018/2019 – No longer recorded in this way</li> </ul> Attachment(s): <ul> <li>none</li> </ul>		
<ul> <li>d. 11 months of the extended period.</li> <li>e. New patients were sign posted to other Providers of this service, commissioned by the CCG, via their GPs. Existing patients were advised by the outgoing Provider to go back to their GP for a new referral. Hearing test prescription data, performed by Regional Hearing Specialists Limited, was made available from their Parent Company. f. None</li> <li>2. None</li> <li>3. 2016/2017 inclusive 2016/2017 - 133 (not including NHS or Third sector) 2017/2018 - 270 (not including NHS or Third sector) 2018/2019 - No longer recorded in this way</li> </ul>		•
<ul> <li>e. New patients were sign posted to other Providers of this service, commissioned by the CCG, via their GPs. Existing patients were advised by the outgoing Provider to go back to their GP for a new referral. Hearing test prescription data, performed by Regional Hearing Specialists Limited, was made available from their Parent Company. f. None</li> <li>2. None</li> <li>3. 2016/2017 inclusive 2016/2017 – 133 (not including NHS or Third sector) 2017/2018 – 270 (not including NHS or Third sector) 2018/2019 – No longer recorded in this way</li> </ul> Attachment(s): none Date response sent:		c. The Provider went out of business.
<ul> <li>commissioned by the CCG, via their GPs. Existing patients were advised by the outgoing Provider to go back to their GP for a new referral. Hearing test prescription data, performed by Regional Hearing Specialists Limited, was made available from their Parent Company.</li> <li>f. None</li> <li>2. None</li> <li>3. 2016/2017 inclusive 2016/2017 – 133 (not including NHS or Third sector) 2017/2018 – 270 (not including NHS or Third sector) 2018/2019 – No longer recorded in this way</li> </ul> Attachment(s): none Date response sent:		
advised by the outgoing Provider to go back to their GP for a new referral. Hearing test prescription data, performed by Regional Hearing Specialists Limited, was made available from their Parent Company. f. None 2. None 3. 2016/2017 inclusive 2016/2017 – 133 (not including NHS or Third sector) 2017/2018 – 270 (not including NHS or Third sector) 2018/2019 – No longer recorded in this way Attachment(s): none Date response sent:		
referral. Hearing test prescription data, performed by Regional Hearing Specialists Limited, was made available from their Parent Company. f. None 2. None 3. 2016/2017 inclusive 2016/2017 – 133 (not including NHS or Third sector) 2017/2018 – 270 (not including NHS or Third sector) 2018/2019 – No longer recorded in this way Attachment(s): none Date response sent:		
Specialists Limited, was made available from their Parent Company. f. None 2. None 3. 2016/2017 inclusive 2016/2017 – 133 (not including NHS or Third sector) 2017/2018 – 270 (not including NHS or Third sector) 2018/2019 – No longer recorded in this way Attachment(s): none Date response sent:		
f. None 2. None 3. 2016/2017 inclusive 2016/2017 – 133 (not including NHS or Third sector) 2017/2018 – 270 (not including NHS or Third sector) 2018/2019 – No longer recorded in this way Attachment(s): none Date response sent:		
<ul> <li>2. None</li> <li>3. 2016/2017 inclusive 2016/2017 – 133 (not including NHS or Third sector) 2017/2018 – 270 (not including NHS or Third sector) 2018/2019 – No longer recorded in this way</li> </ul> Attachment(s): none Date response sent:		
3. 2016/2017 inclusive 2016/2017 – 133 (not including NHS or Third sector) 2017/2018 – 270 (not including NHS or Third sector) 2018/2019 – No longer recorded in this way Attachment(s): none Date response sent:		I. NOTE
2016/2017 – 133 (not including NHS or Third sector) 2017/2018 – 270 (not including NHS or Third sector) 2018/2019 – No longer recorded in this way Attachment(s): none Date response sent:	2.	None
2016/2017 – 133 (not including NHS or Third sector) 2017/2018 – 270 (not including NHS or Third sector) 2018/2019 – No longer recorded in this way Attachment(s): none Date response sent:	3	2016/2017 inclusive
2017/2018 – 270 (not including NHS or Third sector) 2018/2019 – No longer recorded in this way Attachment(s): none Date response sent:	0.	
2018/2019 – No longer recorded in this way          Attachment(s):         none         Date response sent:		
none Date response sent:		
none Date response sent:		
Date response sent:	Attac	hment(s):
03/09/2019		
	03/09	/2019

# FOI 76140 Number of tests

Date request received:		08/08/2019	FOI ref:	76140	
Requ	ested information	tion:			
1.	<ol> <li>Has your CCG contracted out any stool antigen tests for helicobacter pylori testing as part of a block contract with a local hospital or hospitals <u>from January 1, 2018</u> <u>till</u> <u>December 31, 2018</u>?</li> </ol>				
2.	<ol><li>If the answer is 'yes', could you provide me the number of stool antigen tests performed under the block contract during this period.</li></ol>				
3.	3. If the CCG does not have a 'block contract' with a local hospital or hospitals or an external provider can you confirm this.				
<ol> <li>In either case please can you send me the total stool antigen tests for helicobacter pylori testing performed within the CCG <u>from January 1</u>, <u>2018 till December 31, 2018</u></li> </ol>					
Resp	onse:				

Version 1

- 1. Yes, this is part of the block contract with Royal Cornwall Hospital NHS Trust (RCHT) and for the period 1 January 2018 to 31 December 2018 was part of the block contract with University Hospital Plymouth NHS Trust (UHP)
- NHS Kernow does not hold the information requested. For more information please contact: RCHT <u>rcht-tr.foi@nhs.net</u> and UHP <u>plh-tr.foi-</u> <u>requests@nhs.net</u>
- 3. N/A
- NHS Kernow does not hold the information requested. For more information please contact: RCHT <u>rcht-tr.foi@nhs.net</u> and UHP <u>plh-tr.foi-</u> <u>requests@nhs.net</u>

Attachment(s):		
none		
Date response sent:		

16/08/2019

# **GP** Spend

# FOI 75980 Community health services

Date request received:	01/08/2019	FOI ref:	75980		
Requested infor	mation:				
Subject: Procure	ment of GP Direct Access	s Pathology Services			
used durir	the pathology providers, ng financial year 2018/19 ist any provider with a sp	to provide GP direct a	ccess pathology		
	ovide the amount spent w during the year 2018/19.	ith each provider on G	P direct access		
<ul> <li>3. Please state which of following methods for calculating payment best describes the contractual arrangement between the CCG and each provider <ul> <li>a. Amount paid for direct access pathology not explicitly stated, ie included within larger overall contract</li> <li>b. Fixed payment amount for pathology agreed for the year</li> <li>c. Fixed payment amount agreed for the year, but adjusted if volumes are higher or lower than expected</li> <li>d. Payment calculated based on a cost per specialty, eg £X per blood science test, £Y per microbiology sample, £Z per histology case</li> <li>e. Payment calculated on a price per specific test, eg £X for Urea and Electrolytes, £Y for full blood count, £Z for MRSA test</li> </ul> </li> </ul>					

4. Have the authority undertaken a procurement advertised via OJEU for GP direct access pathology during the past five years? If so, please provide link.

#### **Response:**

- a. Royal Cornwall Hospital NHS Trust
   b. University Hospital Plymouth Trust
   a. Northern Deven Lleapital Trust
  - c. Northern Devon Hospital Trust
- 2. a. £5,103,000 b. £1,187,000
  - c. £382,000
- 3. b. Fixed payment amount for pathology agreed for the year
- 4. none

Attachment(s):
None
Date response sent:
07/08/2019

# Individual funding requests

## FOI 76320 Limited clinical effectiveness

Data request	16/08/2019	FOI ref:	76320		
Date request	16/06/2019	FOI rei:	76320		
received:					
Requested information	า:				
Under the Freedom of Ir	nformation Act, please of	an you provide me	with the number		
of applications for prior a	approval made for Proc	edures of Limited C	Clinical		
Effectiveness, and the n					
(2014/15, 2015/16, 2016	•	0			
broken down by proced			in to Marony,		
bloken down by proceed	die.				
		in altrial rad from alternor			
Please can you provide		0	•		
refused in each of the fo					
and 2018/19 (year from	April to March), broken	down by procedur	е.		
Response:					
NHS Kernow does not have a prior approval process and does not use the term					
Procedures of Limited Clinical Benefit.					
The following precedures are these that sit outside the commissioning policies found					
The following procedures are those that sit outside the commissioning policies found					
at <u>http://doclibrary-</u>					

kccg.cornwall.nhs.uk/DocumentsLibrary/KernowCCG/IndividualFundingRequests/Pol

<u>icies/CommissioningPolicies.pdf</u> and handled according to the IFR policy found at <u>https://doclibrary-</u>

kccg.cornwall.nhs.uk/DocumentsLibrary/KernowCCG/IndividualFundingRequests/Policies/IndividualFundingForTreatmentPolicy.pdf

Information relating to the number of individual funding requests for the years 2014/15 to 2017/18 were previously released in date year and the response published on our website: <u>https://doclibrary-</u>

kccg.cornwall.nhs.uk/DocumentsLibrary/KernowCCG/ManagingInformation/FOIRequests/201718/NHSKernowFOIsMarch2018.pdf 2018/19 details

Intervention	Total applications	Declined
Abdominoplasty	Less than 5	Less than 5
Apronectomy	Less than 5	Less than 5
Assisted conception	9	*
Bariatric surgery	Less than 5	Less than 5
Blepharoplasty	Less than 5	Less than 5
Body contouring	Less than 5	Less than 5
Botox	Less than 5	Less than 5
Breast asymmetry correction	Less than 5	Less than 5
Breast augmentation	5	5
Breast implant replacement	Less than 5	Less than 5
Breast reduction	7	7
Cosmetic ear surgery	Less than 5	Less than 5
Cosmetic nose surgery	Less than 5	Less than 5
Ear lobe repair	Less than 5	Less than 5
Gastric band management	Less than 5	Less than 5
Gluten free food	Less than 5	Less than 5
Gynaecomastia	Less than 5	Less than 5
Haemorrhoid surgery	Less than 5	Less than 5
In ear hearing aids	Less than 5	Less than 5
Labiaplasty	Less than 5	Less than 5
Laser hair removal	Less than 5	Less than 5
Laser therapy	Less than 5	Less than 5
Liposuction	Less than 5	Less than 5
Mammoplasty	Less than 5	Less than 5
Mastectomy	Less than 5	Less than 5
Mastopexy	Less than 5	Less than 5
MRI upright scanner	Less than 5	Less than 5
Nipple surgery/asymmetry	Less than 5	Less than 5
Oestrogel implant	Less than 5	Less than 5
Pinnaplasty	Less than 5	Less than 5
Release of palmar fascia	Less than 5	Less than 5
Removal of skin lesion	31	*
Removal of supernumerary nipple	Less than 5	Less than 5
Removal of xanthelasma	Less than 5	Less than 5
Scar revision	Less than 5	Less than 5
Shiatsu	Less than 5	Less than 5
Stammer therapy	Less than 5	Less than 5

Version 1

Tongue tie surgery	Less than 5	Less than 5
Testicular prosthesis	Less than 5	Less than 5
Tonsillectomy	Less than 5	Less than 5
Varicose vein procedures	Less than 5	Less than 5

Please note in line with Section 40 of the Freedom of Information Act 2002 NHS Kernow cannot disclose figures where the number is less than five to prevent the possible identification of individuals.

This also applies to answers marked \* where the number declined was greater than five, but when subtracted from the total made the approved number less than five.

#### Attachment(s):

None

Date response sent:

28/08/2019

# FOI 76230 Exceptional cases

	rmation:			
I would like to ma	rmation:			
I would like to make an FOI request for information on the number of times doctors attempted to get patients treatment through the exceptional cases system in each of the last 5 years? (Exceptional cases as defined by this BBC article: <u>https://www.bbc.co.uk/news/health-40485724</u> ) Please could I also have the information for the number of times these were accepted?				
Response:				
Year	Number of applications made	Number of cases funded		
2014/15	268	61	1	
2015/16	278	52	1	
2016/17	233	60	1	
2017/18	199	21	1	
2018/19	174	31	1	
Attachment(s):				
none				
Date response sent:				
28/08/2019				

# Long term conditions

# FOI 76210 Blood glucose formulary

Date request	09/08/2019	FOI ref:	76210	
received:				
<b>Requested informa</b>	tion:			
I am analysing the prescribing patterns of insulin glargine biosimilars in primary care in England. Part of this study involves estimating the uptake of insulin glargine biosimilars (i.e. Abasaglar and Semglee) and the savings associated with this. From our analyses, we have noticed that GPs belonging to NHS Kernow CCG are amongst the practices with the highest biosimilar adoption rates in England: these were approximately 40% in December 2017 and 51% in December 2018. For this reason, we would like to understand whether NHS Kernow CCG have put in place any policies to incentivise the adoption of biosimilars, in general, as well as insulin glargine biosimilars in particular. Is there any information you may be able to share?				
Response:				
NHS Kernow has not incentivised an increase in the use of biosimilars in general in Cornwall, nor more specifically has it incentivised the uptake of the use of biosimilar glargine insulin. We have supported the review of all people with diabetes who are prescribed analogue insulin and a switch to a biosimilar where this is considered appropriate for, and acceptable to, the individual.				
Attachment(s):				
None				
Date response sent: 15/08/2019				

# FOI 75990 Blood glucose formulary

Date request received:	01/08/2019	FOI ref:	75990	
<b>Requested informat</b>	tion:			
Under the Freedom of hold as below.	of Information Act 200	0, I am requesting info	ormation you may	
<ol> <li>Please confirm if diabetes and the 8 care processes associated with the treatment of diabetes are included in your CCG commissioning plan</li> <li>Is diabetes and the 8 care processes associated part of your CCG improvement and CCG assurance process?</li> <li>Please provide-or sign post (if the plan is available online) me to the relevant</li> </ol>				
improvement	•••••••••••••••••••••••••••••••••••••••	ian is available online)	me to the relevant	

#### Response:

- 1. Yes, diabetes is one of NHS Kernow's key clinical areas. We use the National Diabetes Audit to monitor the eight care processes, however, in line with the Five Year Forward View and long term plan we are focusing on meeting the NICE three treatment targets. We have a Diabetes Oversight group (a multi-disciplinary, multi-organisational group focusing on Diabetes) which has seven workstreams which are listed within attachment 1. Diabetes will remain a priority within our long term strategy.
- 2. Yes, the eight care processes are monitored as per above. Our focus is on the NICE three treatment targets as this is about management and outcomes in line with the national plan whereas the eight care processes is about detection.
- 3. https://www.kernowccg.nhs.uk/your-health/long-term-conditions/diabetes/

Attachment(s):
1. NHS Kernow - Diabetes priority workstreams
Date response sent:
14/08/2019

# Mental health and learning disabilities

## FOI 76600 Bariatric services

Date receiv	request /ed:	30/08/2019	FOI ref:	76600
Requ	ested information	tion:		
<ol> <li>The total number of Continuing Health Care (CHC) packages delivered in the individuals own homes (not care homes or residential facilities), that were managed in the financial year 18/19 (excluding any individual packages under £1,000 per week).</li> </ol>				
2.	<ol> <li>The total <u>value</u> of CHC spend in the financial year 18/19 and for this to be broken down to show spend with third-party providers (Non-NHS bodies)</li> </ol>			
<ol> <li>Total number and value of emergency funded care (outside of CHC funded) packages. Clarification provided - Fast tracked CHC packages</li> </ol>				
4.	Continuing He Mer	ain point of contact at ealth Care packages ir ntal Health ediatrics	the CCG responsible f n the following areas:	or commissioning

Adult

### Response:

- 1. 247
- 2. £40,220,428 All providers are third-party
- 3. Following clarification 2018/19 is 1740 with a spend of £3,707,889
- 4. The director with responsibility for Continuing Health Care is John Groom, Director of Integrated Care (Community)

#### Attachment(s):

none

Date response sent:

24/09/2019

# Miscellaneous

## FOI 76310 Services no longer funded

Date request	15/08/2019	FOI ref:	76310				
received:	13/00/2019	I UITEI.	70310				
Requested information							
Requested morma							
I would like to make an FOI request for a list of procedures/treatments that were funded by the NHS in your CCG in 2014, however no longer receive NHS funding today.							
Response:							
There are no procedures/treatments that were funded by NHS Kernow in 2014, that no longer receive NHS funding today. The current commissioning policies can be found at: <u>https://www.kernowccg.nhs.uk/get-info/individual-funding-requests/treatment-policies/</u>							
Attachment(s):							
none							
Date response sent:							
03/09/2019							

### FOI 76080 Palliative care

Date request received:	07/08/2019	FOI ref:	76080	
Requested information:				

- 1. Please state the name of your CCG or Health Board?
- 2. How many patients currently under the care of your CCG/ Health Board are being kept alive with clinically assisted nutrition and hydration (CANH) who are in a persistent vegetative state or minimally conscious state?
- 3. a. How many patients from Q2 have been kept alive for 1 year or more?b. How many patients from Q2 have been kept alive for 3 years or more?c. How many patients from Q2 have been kept alive for 5 years or more?
- 4. a. How much money did your CCG/Health Board spend on the patients from Q2 in the years;

2015 - 2016 2016 - 2017 2017 - 2018

b. How much money does your CCG/Health Board spend per patient (from Q2) on average?

- 5. How many next of kin of patients from Q2 have asked for the CANH to be stopped and their loved ones be moved into palliative care?
- 6. a. In how many patients cases, have you been in a legal battle, whether mediation or court, because next of kin wanted to stop CANH in the last 5 years?b. What has been the financial cost of these legal battles/mediations?

#### **Response:**

NHS Kernow is a clinical commissioning group responsible for the planning and commissioning of health care services. NHS Kernow does not hold the information requested.

#### Attachment(s):

None

Date response sent: 23/08/2019

23/06/2019

## Organisation

### FOI 76530 Organisation structure

Date request	28/08/2019	FOI ref:	76530
received:			
<b>Requested informa</b>	tion:		
	nder the Freedom of I , for the financial year		o request the

- 1. Did your organisation use an external consultant for any of the following functions:
  - Human Resources
  - Legal Services
  - Leadership and organisational development
  - Board reviews
  - Mediation
  - Regulatory body inspection support
- 2. What were the names of the consultants used?
- 3. What was the expenditure with each consultant?

#### Response:

Spend on consultancy is disclosed in Note 4: Operating expenses in NHS Kernow CCG published accounts: - <u>https://www.kernowccg.nhs.uk/about-us/annual-report/</u>The figures were:

A. 2017/18 £6k

B. 2018/19 zero

- 1. Human Resources only
- The information cannot be disclosed as it could identify the individuals involved and this would constitute a breach of the Data Protection Act 2018. Therefore, this information is exempt from disclosure under section 40(2) of the Freedom of Information Act 2000 on the grounds that it is personal information.
- 3. 2017/18 £6k 2018/19 zero

Attachment(s):
None
Date response sent:
19/09/2019

## FOI 76470 Transformation

Date request received:	27/08/2019	FOI ref:	76470
<b>Requested informati</b>	on:		
In August 2018 the Shaping Our Future transformation board agreed to set up a			
"System Performance and Improvement/Assurance Group."			
Please tell me			
1. How often has this group met?			

- 2. Please tell me who are the individual members?
- 3. Please provide copies of the group's agendas and minutes over the past 12 months, together with any background reports.
- 4. Please provide copies of any reports generated by this group, particularly the "system-wide risk register."
- 5. Please provide copies of any notes made of the group's "workshops.

I am keen to understand how the establishment of this group 12 months ago has made progress towards its initially-stated ambition of moving towards a system of "self-regulation" particularly the Assurance Framework.

#### Response:

In August 2018 the Shaping Our Future transformation board agreed to set up a "System Performance and Improvement/Assurance Group." Please tell me

6. How often has this group met?

The group has met once a month since April 2019.

7. Please tell me who are the individual members?

Membership is detailed on the attendance and apologies sheet at the end of each System Oversight Meeting (SOM) letter. Please note that whilst NHS Kernow usually withholds names under section 40 of the act on this occasion individuals were asked if they were happy to have their names released.

8. Please provide copies of the group's agendas and minutes over the past 12 months, together with any background reports.

These are attached for your information, redacted in accordance with the following exemptions:

Section 40: where consent was not obtained names have been redacted in line with this exemption.

Section 36 – Prejudice to the effective conduct of public affairs.

To release this information would be likely to:

• inhibit the free and frank exchange of advice/views for the purposes of deliberation, sometimes described as the chilling effect.

The accountable person for NHS Kernow has reached a decision of reasonableness regarding these redactions and believes that to release the information redacted may have the effect of chilling the open and honest discussion between partner organisations. The public interest test which followed supported this decision.

9. Please provide copies of any reports generated by this group, particularly the "system-wide risk register."

The group does not receive a system-wide risk register as risks are incorporated into the individual papers received by the meeting, as appropriate. No reports, over and above those attached in relation to item (3), have been produced by the SOM. However, risk registers are published by numerous NHS Bodies in their board papers.

10. Please provide copies of any notes made of the group's "workshops.

Attached is a scoping paper used to suggest the need for two workshops. Only one workshop was held and it resulted in the production of a set of system strategic objectives. A copy of the agreed objectives is also attached.

I am keen to understand how the establishment of this group 12 months ago has made progress towards its initially-stated ambition of moving towards a system of "self-regulation" particularly the Assurance Framework.

The assurance framework in use by the system is the document presented to the Transformation Board – see page 28 onwards on the attached weblink: <u>https://doclibrary-</u>

shapingourfuture.cornwall.nhs.uk/DocumentsLibrary/ShapingOurFuture/TransformationBoardMeeting s/Minutes/1920/201908/Item4app2SystemOperationalPlan201920.pdf

In accordance with discussions at the last Transformation Board (TB's) meeting, the content of this document is currently being reviewed and updated and will be published as part of the TB's papers in due course.

#### Attachment(s):

Date response sent:

24/09/2019

## FOI 76440 Primary care networks

Date request received:	22/08/2019	FOI ref:	76440
Requested information	tion:		
I am requesting the following information:			
Q1 The name of each PCN within the CCG			
Q2 The name of each member GP practice within each PCN			
Q3 The practice code of each member practice			
Q4 The size of each member practice			

### Response:

Information about Primary Care Networks in Cornwall and Isles of Scilly are available on our website: <u>https://www.kernowccg.nhs.uk/get-info/primary-care-networks/</u>

Attachment(s):
None
Date response sent:
09/09/2019
00/00/2010

## FOI 76430 Primary care networks

Date request	21/08/2019	FOI ref:	76430
received:	1•		
Requested informa	tion:		
<ul> <li>We requested information in June and only received/could find partial information.</li> <li>Please may I request information for the below queries:</li> <li>What is the nominated payee within each primary care network.</li> <li>Who is the key person/Clinical Director within each primary care network.</li> </ul>			
Response:			
A full response was sent to the questions raised from your previous request. Copy of NHS Kernow FOI 75200 response attached. Information about Primary Care Networks in Cornwall and Isles of Scilly is available on our website: <u>https://www.kernowccg.nhs.uk/get-info/primary-care-networks/</u>			
Attachment(s):			
Yes			
1. copy of previous FOI response (FOI 75200)			
Date response sent			
09/09/2019	•		

# FOI 76300 Primary care networks

Date request received:	15/08/2019	FOI ref:	76300
<b>Requested informat</b>	tion:		
<ul> <li>some information reg</li> <li>Their names</li> <li>Their clinical c</li> <li>How many pate</li> </ul>	parding the PCNs in yo		ng if I could get

Response:
See attached spreadsheet
Attachment(s):
Yes - NHS Kernow Primary Care Network List
Date response sent:
03/09/2019

# FOI 76170 Primary care networks

Date request	08/08/2019	FOI ref:	76170
received:			
Requested information	tion:		
•	nary information of all eographic footprint of N	5	ks (PCNs) formed or
Care Networks in a s	am requesting was pro standardised form in N as required by the <i>Ne</i>	lay 2019, in the PCNs	initial Network
<ul> <li>Specifically, please provide: <ol> <li>Summary details of all new PCNs':</li> <li>Member general practices (names and NHS Organisation Data Service codes);</li> <li>Non-general practice members / other named stakeholders (names and NHS Organisation Data Service codes where relevant);</li> <li>Clinical Director (name and contact details);</li> <li>Maps of all PCN's geographic area.</li> </ol> </li> </ul>			
	Information on all of the above were provided by all PCNs in <i>Schedule 1</i> of their <i>Network Agreement</i> returns.		
<ol> <li>In addition, please provide details of all primary care General Practices falling within your CCG footprint that have not entered into a PCN Network Agreement.</li> </ol>			
Response:			
<ul> <li>Mevagi</li> <li>Port Isa</li> <li>Wadeb</li> <li>Bottrea</li> <li>Camelf</li> </ul>	CCG has six practices issey aac ridge & Camel Estuar	·	iey are:

Attachment(s):
Yes – NHS Kernow Primary Care Network List
Date response sent:
02/09/2019

# Patient safety and experience

# FOI 76350 Deep vein thrombosis (DVT)

Date request received:	19/08/2019	FOI ref:	76350	
Requested information	n:	L		
thrombosis (DVT) and	ism (VTE) is a collective pulmonary embolism (P 0.3, I80.8-I80.9, I82.9, C	E). VTE is defined	by the following	
QUESTION ONE - VT	E RISK ASSESSMENT	AND DIAGNOSIS		
, ,	are considered to be at oximal and distal DVT?	•	CCG routinely	
Yes				
No				
,	b) For in-patients diagnosed with VTE in your CCG between 1 April 2018 and 31 March 2019, what was the average time from first clinical suspicion of VTE to diagnosis?			
,	nosed with VTE in your vas the average time fro	•		
QUESTION TWO – RO THROMBOSIS	OOT CAUSE ANALYSIS	S OF HOSPITAL-A	SSOCIATED	
According to Service C provider must:	ondition 22 of the NHS	Standard Contract	2017/19, the	
"Perform Root Cause A	Analysis of all confirmed	cases of pulmonar	y embolism and	

Version 1

deep vein thrombosis acquired by Service Users while in hospital (both arising during a current hospital stay and where there is a history of hospital admission within the last 3 months, but not in respect of Service Users admitted to hospital with a confirmed venous thromboembolism but no history of an admission to hospital within the previous 3 months)..."

The provider must report the results of those Root Cause Analyses to the coordinating commissioner on a monthly basis.

a) How many cases of hospital-associated thrombosis (HAT) were recorded in your CCG in each of the following quarters?

Quarter	Total recorded number of HAT
2018 Q2 (Apr –Jun)	
2018 Q3 (Jul – Sep)	
2018 Q4 (Oct – Dec)	
2019 Q1 (Jan – Mar)	

b) How many Root Cause Analyses of confirmed cases of HAT were performed in each of the following quarters?

Quarter	Number of Root Cause Analyses performed
2018 Q2 (Apr – Jun)	
2018 Q3 (Jul – Sep)	
2018 Q4 (Oct – Dec)	
2019 Q1 (Jan – Mar)	

c) According to the Root Cause Analyses of confirmed HAT in your CCG between 1 April 2018 and 31 March 2019, in how many cases:

Did patients have distal DVT?	
Did patients have proximal DVT?	
Were patients receiving thromboprophylaxis prior to	
the episode of HAT?	
Did HAT occur in surgical patients?	
Did HAT occur in general medicine patients?	
Did HAT occur in cancer patients?	

## QUESTION THREE – ADMISSION TO HOSPITAL FOR VTE

a) How many patients were admitted to your CCG for VTE which occurred outside of a secondary care setting between 1 April 2018 and 31 March 2019?

b)	Of these patient	s, how many:
----	------------------	--------------

Had a previous inpatient stay in your CCG up to 90	
days prior to their admission?	
Were care home residents?	
Were female?	
Were male?	

c) Of the patients admitted to your CCG for VTE occurring between 1 April 2018 and 31 March 2019 who had a previous inpatient stay in your CCG up to 90 days prior to their admission, how many had their VTE risk status recorded in their discharge summary?

d) Please describe how your CCG displays a patient's VTE risk status in its discharge summaries.

## **QUESTION FOUR – PHARMACOLOGICAL VTE PROPHYLAXIS**

a) How many VTE patients who were eligible received pharmacological VTE prophylaxis between 1 April 2018 and 31 March 2019?

b) How many of VTE patients who were eligible received pharmacological VTE prophylaxis within 14 hours of admission between 1 April 2018 and 31 March 2019?

## **QUESTION FIVE – VTE AND CANCER**

a) How many patients has your CCG treated for cancer (of all types) in each of the past three years?

Version 1

2016	
2017	
2018	

b) Of the patients treated for cancer, how many also had a diagnosis of venous thromboembolism (VTE) {VTE is defined by the following ICD 10 codes: I80.0-I80.3, I80.8-I80.9, I82.9, O22.2 – O22.3, O87.0 – O87.1, I26.0, and I26.9} in each of the past three years?

2016	
2017	
2018	

c) Of the patients treated for cancer who also had a diagnosis of VTE in each of the past three years, how many:

	2016	2017	2018
Were receiving chemotherapy?			
Had metastatic disease?			
Had localised disease?			
Were treated for brain cancer?			
Were treated for lung cancer?			
Were treated for uterine cancer?			
Were treated for bladder cancer?			
Were treated for pancreatic cancer?			
Were treated for stomach cancer?			
Were treated for kidney cancer?			

d) In how many patient deaths within your CCG was cancer (of any type) listed as the **primary** cause of death in each of the past three years:

2016	
2017	
2018	

e) Of the patients who died within your CCG, in how many was VTE as well as cancer listed as a cause of death in each of the past three years:

2016	
2017	
2018	

f) Of the patients who died in your CCG who had both VTE and cancer listed as a cause of death, how many:

	2016	2017	2018
Were receiving chemotherapy?			

Were treated for brain cancer?		
Were treated for lung cancer?		
Were treated for uterine cancer?		
Were treated for bladder cancer?		
Were treated for pancreatic cancer?		
Were treated for stomach cancer?		
Were treated for kidney cancer?		

**g)** Are ambulatory cancer patients who are receiving chemotherapy in your CCG routinely risk assessed for their risk of developing CAT/VTE?

Yes	
No	

**h)** Are ambulatory cancer patients who are receiving chemotherapy AND deemed at high risk of developing CAT/VTE offered pharmacological thromboprophylaxis with? Please tick/cross all those appropriate.

Low-molecular-weight heparin (LMWH)	
Direct Oral AntiCoagulants (DOAC)	
Aspirin	
Warfarin	
Other	
None	

### **QUESTION SIX – PATIENT INFORMATION**

The NICE Quality Standard on VTE Prevention stipulates that patients/carers should be offered verbal and written information on VTE prevention as part of the admission as well as the discharge processes.

a) What steps does your CCG take to ensure patients are adequately informed about VTE prevention? (*Tick each box that applies*)

	Distribution of own patient information leaflet	
	Distribution of patient information leaflet produced by an external organisation	
	If yes, please specify which organisation(s):	
	Documented patient discussion with healthcare professional	
	Information provided in other format (please specify)	
, ,	G provides written information on VTE prevention, does it provides written information on VTE prevention, does it provides that applied a start applied of the start applied of t	

 $\square$ 

Yes

If yes, please spec languages:	ify which
No	

## QUESTION SEVEN – COST OF VTE IN YOUR AREA

 a) Does your CCG have an estimate of the cost of VTE to the NHS locally (including cost of treatment, hospital bed days and litigation costs) for 2018/19? (Please tick one box)

Yes	
No	

If 'Yes', please specify the estimated cost:

b) Please indicate the cost-estimate for the following areas of VTE management and care, as well as the corresponding number of VTE hospitalisations/ readmissions/ treatments that occurred between 1 April 2018 and 31 March 2016.

VTE management and care	Cost-estimate	Corresponding patient numbers
VTE hospitalisations		
VTE re-admissions		
VTE treatments (medical and mechanical thromboprophylaxis)		
VTE litigation/negligence costs		

#### Response:

#### • Questions one, two c, three to seven

NHS Kernow is a clinical commissioning group responsible for the planning and commissioning of health care services. NHS Kernow does not hold the information for more information please contact, (RCHT) Royal Cornwall NHS Trust: <u>rch-tr.foi@nhs.net</u>

#### Question two

quarter	(a) total recorded number of hat	(b) Number of Root Cause Analyses	
		performed	

2018 q2 (Apr –Jun)	less than 5	zero	
2018 q3 (Jul – Sep)	less than 5	less than 5	
2018 q4 (Oct – Dec)	less than 5	less than 5	
2019 q1 (Jan – Mar)	less than 5	less than 5	

NHS Kernow holds the information for questions 2a and b. Where the number is very low (fewer than 5) the information cannot be disclosed as it could potentially identify the individuals involved, especially if combined with other data, this would constitute a breach of the Data Protection Act 2018. Therefore, this information is exempt from disclosure under section 40(2) of the Freedom of Information Act 2000 on the grounds that it is personal information.

#### Attachment(s):

None Date response sent: 12/09/2019

## FOI 76240 Prescribing recommendations

Date I	request	13/08/2019	FOI ref:	76240	
receiv	received:				
Requ	ested informat	tion:			
		uest answers to the fo Illient flammability:	llowing based upon th	e December 2018	
1.		nation provided by the healthcare professio	e MHRA been implem nals?	ented across your	
2.	How has this lintentions.	peen implemented? P	lease also provide de	tails of any future	
3.	Has this information provided by the MHRA been implemented across your CCG to advise the public on how to use emollient skin products safely?				
4.	<ol> <li>How has this been implemented? Please also provide details of any future intentions.</li> </ol>			tails of any future	
Respo	onse:				
1.	Yes.				
2.	Optimisation to weekly newsle GP practice in	eam communicated the trees of the present to the present to the present to the present of the pr	report, NHS Kernow M nis safety concern on f ribing lead and practic f Scilly, beginning first urch 2014, 25 April 201	our occasions via a e manager of each in March 2014 and	

Version 1

In January 2019 a reminder was sent to all GP practices following the updated Drug Safety Update.

- 3. Yes.
- In 2014 NHS Kernow included information for the public, carers and healthcare professionals on its formulary website: <u>https://www.eclipsesolutions.org/Cornwall/info.aspx?chapterid=16</u>. NHS Kernow Medicines Optimisation team also prepared a similar communication which was sent to community pharmacies reminding them of the safety advice.

# Attachment(s):

None.

Date response sent:

03/09/2019

# Prescribing and pharmacies

## FOI 76550 Enhanced service contracts

Date request received:	28/08/2019	FOI ref:	76550
Requested informa	tion:		
service contracts as	day to request the foll held by NHS Kernow	CCG.	
involving pros	ntly have any enhance state cancer and/or Le IRHa) administration v	uteinising Hormone	,
	ii. iii.		) n) )
	- What is the frequen le breakdown by drug		ere possible please
	- What is the paymen down by drug name.	t amount? Where p	ossible please provide
For the above	(a-c) please use the	table below to captu	ire.
Drug name	Frequer	icy of payment P	ayment amount

Zoladex (Goserelin)	
Prostap (Leuprorelin)	
Lutrate (Leuprorelin)	
Decapeptyl (Triptorelin)	

- 2. If you do have a service, does the service include payment for other activities, specifically:
  - PSA Y/N
  - symptom questionnaires Y/N
  - patient review follow ups Y/N
  - Other (please specify)
  - a. What is the payment amount for these activities? Please where possible provide a breakdown by activity name

# Response:

- 1. No
- 2. n/a

#### Attachment(s):

None

#### Date response sent:

03/09/2019

# **Referral management**

# FOI 76460 Procedures of limited clinical effectiveness

Date request received:	23/08/2019	FOI ref:	76460
Requested information	tion:		

I'm looking into POLCE policies, the referral management system, for all CCGs in England and would like a few questions to be answered under the Freedom of Information Act.

For your information, POLCE refers to Procedures of Limited Clinical Effectiveness, but is previously known as 'low priority treatments'. Please treat POLCE in this request as referring to 'Procedures of Limited Clinical Effectiveness' and what was previously called 'low priority treatments'.

If the CCG **does** follow a POLCE policy, please could you provide answers to each following question covering the following time periods:

The first covering the time period 1<sup>st</sup> January 2015 – 31<sup>st</sup> December 2015; The second covering the time period 1<sup>st</sup> January 2016 – 31<sup>st</sup> December 2016; The third covering the time period 1<sup>st</sup> January 2017 – 31<sup>st</sup> December 2017; and the fourth covering the time period 1<sup>st</sup> January 2018 – 31<sup>st</sup> December 2018; and the fifth covering the time period 1<sup>st</sup> January 2019 – 1<sup>st</sup> August 2019.

- 1. For each time period, how many applications were approved and referred?
- 2. For each time period, how many applications were rejected?

#### Response:

NHS Kernow Clinical Commissioning Group has a Referral Management Service (RMS) which manages referrals for 50 GP practices. In addition, NHS Kernow commissions Devon Referral Support Services (DRSS) to manage referrals for the remaining 9 practices in the county. They triage referrals against the commissioning policies published by NHS Kernow. The outcome of this triage was:

Time period	Accepted	Returned
01/01/15 -	1384	744
31/12/15		
01/01/16 -	1421	889
31/12/16		
01/01/17 –	1574	652
31/12/17		
01/01/18 –	1472	548
31/12/18		
01/01/19 -	525	282
01/08/19		

Please note, that this will not be a full picture as not all policies are able to be enforced by the referral management centres as some procedures will only be determined after an initial consultation with the relevant specialist.

Attachment(s):	
None	
Date response sent:	
16/09/2019	

## FOI 76410 Glaucoma

Date receiv	request ved:	21/08/2019	FOI ref:	76410		
Requested information:						
<ol> <li>Do you have contracts in place for the diagnosis, and monitoring of glaucoma?</li> </ol>						
2.	Can you please confirm the providers who are currently accredited to deliver this service?					
3.	Can you please confirm whether the CCG paid any 'non-contracted' providers for the delivery of the service?					
4	Can vou pleas	e confirm the servic	e pathway and red	uirements for the current		

diagnosis and monitoring of Glaucoma pathways?

- 5. Can you please confirm the tariffs that the CCG currently pays for each part of the Glaucoma Diagnosis and Monitoring Pathway?
- 6. Can the CCG please confirm the number of episodes that they paid for under each part of the Glaucoma Diagnosis and Monitoring Pathway during the following periods?
  - April 2017-March 2018
  - April 2018 March 2019
  - April 2019 July 2019
- 7. Can the CCG please provide a copy of the service specification for each part of the Glaucoma Diagnosis and Monitoring Pathway?
- 8. Can the CCG please confirm when the current contracts for Glaucoma Diagnosis and Monitoring Pathways both started, and are due to expire?
- 9. Can you please confirm if the current contract has an option to further extend? If so, for how long?
- 10. Can the CCG please confirm their intentions on what happens with the Glaucoma Diagnosis and Monitoring when they expire?

#### Response:

- 1. Yes
- 2. Royal Cornwall NHS Hospital Trust (RCHT), University Hospitals Plymouth NHS Trust (UHPT), Royal Devon and Exeter NHS Foundation Trust (RDE), Northern Devon Healthcare NHS Trust (NDHT)
- 3. Yes, if patients were treated out of the area.
- 4. No current service specifications in place to cover these services
- 5. National tariff
- 6. NHS Kernow does not hold the information requested. This may be available from the providers.
- 7. No current service specifications in place to cover these services
- 8. Annual renewal with acute trusts
- 9. Annual renewal with acute trusts
- 10. Annual renewal with acute trusts

Attachment(s):
None
Date response sent:
12/09/2019

## FOI 76290 Referral triage service

Date request received:	14/08/2019	FOI ref:	76290		
Requested information:					
<ol> <li>Do you operate a referral triage service, referral triage centre, referral management service or referral management centre?</li> </ol>					
2. If so, who is the named contact for this service?					

## **Response:**

- 1. Yes, NHS Kernow utilises 2 referral management centres covering Cornwall and the Isles of Scilly.
- 2. This information is contained on our website: https://www.kernowccg.nhs.uk/get-info/referral-management-service/

News	
None	
Date response sent:	
16/08/2019	

# Women's health

# FOI 76590 IVF treatment

Data request	29/08/2019	FOI ref:	76590
Date request	29/06/2019	FOI rei:	76590
received:			
Requested infor	nation:		
	formation about the fund h, I would like to know th		
<ol> <li>If no, when</li> <li>What are the</li> </ol>	CG fund IVF treatment? did the CCG stop offeri ne current criteria set ou set in order to successfu	ng funding for IVF trea t by the CCG that wom	nen under the age of
	full cycles of IVF will the f these criteria?	CCG fund if a womar	under the age of 40
	ne current criteria set ou in order to successfully		•
	full cycles of IVF will the f these criteria?	CCG fund if a womar	aged 40 to 42
are the cur	CG fund IVF treatment rent criteria set out by th y qualify for NHS-funded	e CCG that women m	
	full cycles of IVF will the f these criteria?	e CCG fund if a womar	over the age of 42
Response:			
1. Yes. 2. n/a			
Questions 3 to	8. NHS Kernow commi ://www.kernowccg.nhs.u	•••	

Attachment(s):	
None	
Date response sent:	
16/09/2019	